Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Pioglitazone Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
Pioglitazone Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Dapagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
dapagliflozin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ARF6 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ARF6, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Pemigatinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
pemigatinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Rituximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
rituximab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Filgotinib Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
filgotinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Certolizumab Pegol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
certolizumab pegol: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ARF1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ARF1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Infliximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
infliximab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Varenicline Tartrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
varenicline nasal spray: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Nitisinone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
nitisinone: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Sapropterin Dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
sapropterin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.